Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 21Capecitabine 17Fluorouracil 15Irinotecan 11Radiotherapy 10Leucovorin 8Cetuximab 6Bevacizumab 6Gemcitabine 5oblimersen 3fludarabine 3aldesleukin 3Nivolumab 3Erlotinib Hydrochloride 3Cyclophosphamide 3labetuzumab 2dehydroftorafur 2conatumumab 2Tomography, X-Ray Computed 2Receptor Protein-Tyrosine Kinases 2Radiation 2Panitumumab 2Neoadjuvant Therapy 2Magnetic Resonance Imaging 2Interleukin-2 2Gefitinib 2Electrocardiography 2Diphenhydramine 25,10-methylenetetrahydrofolic acid 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rectal Neoplasms × CB-839 × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡